Richter Gedeon receives FDA acceptance: what it means for Richter Gedeon stock
Published on 10/17/2026 at 10:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming dates and regulatory news
- Richter Gedeon received FDA acceptance for the FYLREVY application in the U.S. on October 14, 2026.
- The next Xetra session is scheduled for October 19, 2026.
- Gedeon Richter's investor page lists the FYLREVY announcement dated October 14, 2026.
Richter Gedeon received FDA acceptance for a new drug application for FYLREVY in the U.S. on October 14, 2026, according to the issuer's investor announcements. The regulatory filing is the most recent dated company development identified for the pharmaceutical group.
Market context: Market report BUX.
FYLREVY filing and upcoming dates
The issuer's investor page lists the FYLREVY announcement among its latest announcements and dates it October 14, 2026. The announcement concerns acceptance of a new drug application for U.S. review. The source does not establish an approval decision or a launch date.
Weekend trading and the next session
Xetra is closed during the publication window. The next Xetra session is October 19, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Richter Gedeon stock.
